CD33 and myelodysplastic syndrome: Ultra-CAR-T, simultaneously expressing CD33 and IL-15, was used in R/R AML and high-risk MDS patients in a phase I dose-finding, trial (NCT03927261): ORR was 50%, with good safety and tolerability [161].